NDAINTRAVENOUSPOWDER
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
3
Data completeness
4/8 — Partial
UPTRAVI (selexipag) by Johnson & Johnson is prostacyclin receptor agonists [moa]. First approved in 2021.
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UPTRAVI (selexipag) is a small-molecule prostacyclin receptor agonist approved in July 2021 for intravenous administration as a powder formulation. It works by selectively activating prostacyclin receptors to promote vasodilation and inhibit platelet aggregation. The drug is indicated for pulmonary arterial hypertension (PAH) patients requiring parenteral therapy.
Peak4.5 years to LOE
Product is at peak commercial maturity with 4.6 years of patent protection remaining; brand teams should prepare for competitive pressures and LOE mitigation strategies.
Mechanism of Action
Prostacyclin Receptor Agonists
Pharmacologic Class:
Prostacyclin Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
Started Oct 2020
20 enrolled
Pulmonary HypertensionSchistosomiasis
A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag
Started Oct 2020
372 enrolled
Pulmonary Arterial Hypertension
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
Started May 2017
0Pulmonary Arterial Hypertension
Why This Matters for Your Career
Worked on UPTRAVI at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.